[go: up one dir, main page]

RU2001111808A - PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF ROTARY AND LEFT ROTARY ISOMERS OF SOTALOL - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF ROTARY AND LEFT ROTARY ISOMERS OF SOTALOL

Info

Publication number
RU2001111808A
RU2001111808A RU2001111808/14A RU2001111808A RU2001111808A RU 2001111808 A RU2001111808 A RU 2001111808A RU 2001111808/14 A RU2001111808/14 A RU 2001111808/14A RU 2001111808 A RU2001111808 A RU 2001111808A RU 2001111808 A RU2001111808 A RU 2001111808A
Authority
RU
Russia
Prior art keywords
isomers
sotalol
pharmaceutical composition
pharmaceutically acceptable
combination
Prior art date
Application number
RU2001111808/14A
Other languages
Russian (ru)
Other versions
RU2213560C2 (en
Inventor
Алангуди САНКАРАНАРАЯНАН
Original Assignee
Торрент Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN89KO1999 external-priority patent/IN188162B/en
Application filed by Торрент Фармасьютикалз Лтд. filed Critical Торрент Фармасьютикалз Лтд.
Publication of RU2001111808A publication Critical patent/RU2001111808A/en
Application granted granted Critical
Publication of RU2213560C2 publication Critical patent/RU2213560C2/en

Links

Claims (9)

1. Фармацевтическая композиция для использования в качестве антиаритмического лекарственного средства с регулируемой бетаадренергической блокадой, которая включает комбинацию правовращающего и левовращающего изомеров соталола или их фармацевтически приемлемых солей в качестве активного ингредиента, причем интервал соотношений правовращающего и левовращающего изомеров в указанной комбинации представляет от 1,5: 1 до 3,5: 1.1. The pharmaceutical composition for use as an antiarrhythmic drug with controlled beta-adrenergic blockade, which includes a combination of dextrorotatory and levorotatory isomers of sotalol or their pharmaceutically acceptable salts as an active ingredient, and the range of ratios of dextrorotatory and levorotatory isomers in this combination is from 1.5: 1 to 3.5: 1. 2. Фармацевтическая композиция по п. 1, в которой соотношение правовращающего и левовращающего изомеров соталола или их фармацевтически приемлемых солей составляет 3: 1. 2. The pharmaceutical composition according to claim 1, in which the ratio of dextrorotatory and levorotatory isomers of sotalol or their pharmaceutically acceptable salts is 3: 1. 3. Фармацевтическая композиция по п. 1, в которой соотношение правовращающего и левовращающего изомеров соталола или их фармацевтически приемлемых солей составляет 2: 1. 3. The pharmaceutical composition according to claim 1, in which the ratio of the dextrorotatory and levorotatory isomers of sotalol or their pharmaceutically acceptable salts is 2: 1. 4. Фармацевтическая композиция по п. 1, в которой изомеры находятся в виде их гидрохлоридных солей. 4. The pharmaceutical composition according to claim 1, in which the isomers are in the form of their hydrochloride salts. 5. Фармацевтическая композиция по п. 2, в которой изомеры находятся в виде их гидрохлоридных солей. 5. The pharmaceutical composition according to claim 2, in which the isomers are in the form of their hydrochloride salts. 6. Фармацевтическая композиция по п. 3, в которой изомеры находятся в виде их гидрохлоридных солей. 6. The pharmaceutical composition according to claim 3, in which the isomers are in the form of their hydrochloride salts. 7. Пероральный препарат для лечения кардиологического заболевания у млекопитающих, включая людей, который содержит комбинацию правовращающего и левовращающего изомеров соталола или их фармацевтически приемлемых солей в соотношении, которое заявлено в п. 1, в качестве активного ингредиента в смеси с фармацевтически приемлемым наполнителем и добавками, и, необязательно, одним или более из других фармакологически активных соединений. 7. An oral preparation for the treatment of a cardiological disease in mammals, including humans, which contains a combination of the dextrorotatory and levorotatory isomers of sotalol or their pharmaceutically acceptable salts in the ratio as claimed in claim 1, as an active ingredient in a mixture with a pharmaceutically acceptable excipient and additives, and, optionally, one or more of the other pharmacologically active compounds. 8. Парентеральный препарат для лечения кардиологического заболевания у млекопитающих, включая людей, который содержит комбинацию правовращающего и левовращающего изомеров соталола или их фармацевтически приемлемых солей в соотношении, которое заявлено в п. 1, в качестве активного ингредиента в смеси с фармацевтически приемлемым наполнителем и добавками, и, необязательно, одним или более из других фармакологически активных соединений. 8. A parenteral preparation for the treatment of a cardiological disease in mammals, including humans, which contains a combination of the dextrorotatory and levorotatory isomers of sotalol or their pharmaceutically acceptable salts in the ratio as claimed in claim 1, as an active ingredient in admixture with a pharmaceutically acceptable excipient and additives, and, optionally, one or more of the other pharmacologically active compounds. 9. Способ лечения кардиологического заболевания у млекопитающих, включая людей, который включает введение оптимально эффективного количества комбинации правовращающего и левовращающего изомеров соталола или их фармацевтически приемлемых солей, как заявлено в п. 1. 9. A method of treating a cardiological disease in mammals, including humans, which comprises administering an optimally effective amount of a combination of the dextrorotatory and levorotatory isomers of sotalol or their pharmaceutically acceptable salts, as claimed in paragraph 1.
RU2001111808/14A 1999-02-05 1999-02-22 Pharmaceutical composition containing combination of dextrorotatory and levorotatory isomers of sotalol RU2213560C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN89KO1999 IN188162B (en) 1999-02-05 1999-02-05
IN89/CAL/99 1999-02-05

Publications (2)

Publication Number Publication Date
RU2001111808A true RU2001111808A (en) 2003-03-20
RU2213560C2 RU2213560C2 (en) 2003-10-10

Family

ID=38668683

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001111808/14A RU2213560C2 (en) 1999-02-05 1999-02-22 Pharmaceutical composition containing combination of dextrorotatory and levorotatory isomers of sotalol

Country Status (20)

Country Link
US (1) US6281246B2 (en)
EP (1) EP1146865B9 (en)
JP (1) JP2002536324A (en)
CN (1) CN1149987C (en)
AT (1) ATE241349T1 (en)
AU (1) AU761521C (en)
BR (1) BR9915951A (en)
CA (1) CA2348882C (en)
CZ (1) CZ20011807A3 (en)
DE (1) DE69908421T2 (en)
DK (1) DK1146865T3 (en)
ES (1) ES2195538T3 (en)
HK (1) HK1041206B (en)
HU (1) HU224033B1 (en)
IN (1) IN188162B (en)
PL (1) PL351143A1 (en)
PT (1) PT1146865E (en)
RU (1) RU2213560C2 (en)
SE (1) SE1146865T5 (en)
WO (1) WO2000045807A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
DK2024329T3 (en) * 2006-05-18 2013-11-04 Dompe Spa (2R) -2 - [(4-SULPHONYL) AMINOPHENYL] PROPANAMIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN102329254B (en) * 2010-07-12 2014-02-05 上海奥博生物医药技术有限公司 Method for preparing N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]methylsulfonyl benzylamine hydrochloride
BE1021320B1 (en) * 2014-08-27 2015-10-29 Hyloris Pharmaceuticals SA PHARMACEUTICAL COMPOSITION READY FOR USE
BE1021328B1 (en) * 2014-08-27 2015-10-30 Hyloris Pharmaceuticals SA PHARMACEUTICAL COMPOSITION READY FOR USE
FR3050297A1 (en) * 2016-04-13 2017-10-20 Assist Publique - Hopitaux De Paris METHOD OF DETERMINING INDUSTRY SUSCEPTIBILITY OF TORSADE DE POINTS
CN109419779B (en) * 2017-09-04 2021-05-25 鲁南制药集团股份有限公司 Sotalol hydrochloride preparation
CN109419780B (en) * 2017-09-04 2021-05-11 张家港市中医医院 A kind of sotalol hydrochloride tablet and preparation method thereof
CN107982237B (en) * 2018-01-17 2018-11-23 安宁 Sotalol hydrochloride preparation and preparation method thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089526A (en) * 1983-05-23 1992-02-18 Bristol-Myers Company Antiarrhythmic class III process
JPH01165569A (en) * 1987-12-22 1989-06-29 Mitsui Toatsu Chem Inc Production of optically sotalol
IES61567B2 (en) * 1994-02-17 1994-11-16 Russinsky Ltd Pharmaceutical products

Similar Documents

Publication Publication Date Title
RU2001111808A (en) PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF ROTARY AND LEFT ROTARY ISOMERS OF SOTALOL
KR100236666B1 (en) Compositions and uses thereof containing tramadol and codeine, oxycodone or hydrocodone
CA1121726A (en) Drug for the treatment of the central nervous system
RU93057724A (en) PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARATION AND METHOD OF TREATMENT
ES2295609T3 (en) TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN.
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
CZ187097A3 (en) Pharmaceutical preparation
ITRM920155A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 3-2 (DIMETHYLAMINE) ETHYL-N-METHYL-INDOL-5-METHANAL SULPHONAMIDE, RELATIVE PROCEDURE FOR PREPARATION AND USE OF THE SAME IN TREATMENT OF MAMMALS
JP2004524337A (en) Novel use of a peptide class of compounds to treat allodynia and various other types of chronic pain or phantom limb pain
RU2000106597A (en) NEW APPLICATION OF BUDESONIDE AND FORMOTHEROL
JP2000507544A (en) How to treat pain
KR102372194B1 (en) Treatment of multiple sclerosis using LSD1 inhibitors
EA200400007A1 (en) PHARMACEUTICAL COMPOSITION FOR THE EFFICIENT INTRODUCTION OF APOMORPHIN, 6aR - (-) - N-PROPYL-NORAPOMORPHIN, THEIR DERIVATIVES AND THEIR PROCEDURES
KR930005969A (en) Tramadol N-oxides and enantiomers and compositions thereof, and uses thereof
CA2303815A1 (en) N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
SE9901573D0 (en) New compounds
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
RU2004135078A (en) HERBAL MOLECULE AS A POTENTIAL ANTI-VEHICLE MEDICINE
US6326404B1 (en) Use of O-desmethyl-N-mono-desmethyl-tramadol
WO2004096118B1 (en) Composition for improving cognition and memory
CN1382145A (en) Remedies for neuropathic pain and model animals of neuropathic pain
JP4933265B2 (en) Flupirtine and tramadol combination
KR0149491B1 (en) 7-Substituted amino-8-substituted carbonyl-methylamino-1-oxaspiro (4,5) decane as a cerebrovascular disorder treatment
AU2003240113A1 (en) Formulation of nefopam and its use in the treatment of pain